A seasoned technology entrepreneur with a diverse international background in senior and executive leadership roles across the technology, biotechnology, medical device, and healthcare investment sectors worldwide. Having lived in Asia for almost 20 years, a fluent Japanese speaker and now a Singapore Permanent Resident, I embarked on my professional journey with Adtec Corporation K.K., a semiconductor trading company listed on the Tokyo Stock Exchange (Jasdaq), now known as AKIBA Holdings (6840:Tokyo). During my tenure, I held the position of Director for the UK & Europe, based in Tokyo and later London. Playing a pivotal role in the acquisition of Adtec Corporation by Shinden Hightex Corporation (3131:Tokyo) in 2005, I continued serving as a Director in London.Transitioning to a private family office in Hong Kong in 2009, I specialized in healthcare investments, where we identified ground-breaking innovators and disruptors in medical technology across various sectors, including devices, diagnostics, therapeutics, and natural health products.In 2012, I co-founded Nova Satra Health Sdn. Bhd. to seize opportunities in medical technology advancements, leading to the establishment of Nova Satra Dx Pte Ltd., a molecular diagnostic developer based in Singapore, in 2014, which was later backed by Malaysian conglomerate Genting Berhad.The significant merger of Nova Satra Dx with INEX Innovations Exchange in August 2019, valued at US$72 million, resulted in the creation of INEX Innovate. During my tenure as Chief Executive of the merged entity, the team expanded from 10 members to over 50, introducing numerous cutting-edge medical diagnostic technologies and garnering multiple awards, including being ranked the second fastest growing healthcare company in Singapore and 7th in the Asia Pacific by the Financial Times. In 2020, I was honored with an invitation to join the National University of Singapore's NUS Medicine International Council as a Council Member. Furthermore, in 2022, my contributions were recognized with the Ernst & Young Singapore Entrepreneur of The Year award in the Biotechnology category.In 2024 I stood down as Chief Executive of INEX Innovate, transitioning to the Board of the company as Non-Executive Director and in April 2024 I was appointed Chief Executive Officer of London Stock Exchange listed investment company IKIGAI Ventures Limited (LSE:IKIV).I hold degrees from Bond University and Griffith University, Australia.